Clinical Efficacy of Argatroban Sequential Therapy Combined with rt-PA Thrombolysis in the Treatment of Acute Ischemic Stroke
[Objective]To investigate the clinical efficacy of argatroban sequential therapy combined with alte-plase(rt-PA)thrombolysis in the treatment of acute ischemic stroke(AIS).[Methods]The clinical data of 96 patients with AIS treated in our hospital from May 2020 to December 2022 were retrospectively analyzed.According to the different treatment schemes,they were divided into observation group and control group,with 48 cases in each group.The control group was given rt-PA thrombolysis,while the observation group was given argatroban sequential thera-py on the basis of thrombolysis.The efficacy,neurological injury factors[S100βprotein,neuron specific enolase(NSE)],vascular endothelial injury indicators[serum calcitonin gene-related peptide(CGRP),endothelin-1(ET-1)],National Institutes of Health Stroke Scale(NIHSS),modified Rankin Scale(mRS),Barthel Index(BI)score and the incidence of complications were compared between the two groups.[Results]After 3 months of treatment,the total effective rate of the study group was higher than that of the control group(P＜0.05);After 14 days and 3 months of treatment,S100βand NSE in the observation group were lower than those in the control group(P＜0.05);After 14 days and 3 months of treatment,CGRP in the observation group was higher than that in the control group,and ET-1 was lower than that in the control group(P＜0.05);After 3 months of treatment,the NIHSS and mRS scores of the observation group were lower than those of the control group,and the BI score of the observation group was high-er than that of the control group(P＜0.05);There was no significant difference in the total incidence of complica-tions between the two groups(P＞0.05).[Conclusion]The effect of argatroban sequential therapy combined with al-teplase in the treatment of AIS is significant,which can reduce vascular endothelial injury,improve neurological func-tion and improve living ability.
万方数据
维普
